Genmab — Juli 2020
-
Janssen's Wildgust Breaks Down Bispecific Antibodies in Development for Non-Small Cell Lung Cancer and Multiple Myeloma https://www.ajmc.com/journals/evidence-based-oncology/2020/july-2020/janssens-wildgust-breaks-down-bispecific-antibodies-in-development-for-nonsmall-cell-lung-cancer-and-multiple-myeloma
-
this is that article in pdf form in the AJMC journal
https://ajmc.s3.amazonaws.com/_media/_pdf/EBO_07_2020_ASCO_LowRes.pdf -
God morgen.
-
BionTech er det biotekselskab i Europa med højest marketcap. USD 23.8 milliarder mod Genmabs USD 23.6 milliarder!
-
more management
hires https://twitter.com/Genmab/status/1286024892010430465 -
Ocrevus in MS
Market leadership in US continues with 21% total patient share. 25% sales growth in H1 at CHF 2.1 billion..
Full Roche presentation https://www.roche.com/dam/jcr:6581a61d-c326-4708-a376-6780b2735e5d/en/irp200723.pdf -
Om kursmål generelt: https://www.proinvestor.com/index.php?p=debat_1&postid=85300
-
Bla. om kursmål i biotek.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind